Abstract.A female patient (64 years of age; body mass index, 26) had a markedly and relatively low low-density lipoprotein-cholesterol (LDL-C) level (97 mg/dl) despite high serum total cholesterol (TC) (331 mg/dl) and triacylglyceride levels (307 mg/dl). Since the expected LDL-C was 222 mg/dl, there was a significant difference between the calculation and measurement based on direct enzyme assay. Only 30% of serum cholesterol was associated with LDL-C in this patient. To determine the basis for the markedly low LDL-C/TC ratio, we isolated and analyzed lipoproteins from the patient as well as age-and gender-matched controls. The patient had lowered serum CETP activity and elevated paraoxonase activity with GOT and GPT values in the normal range. The very low-density lipoprotein particles from the patient were larger than those of the controls and enriched with lipid and protein, while the LDL from the patient (LDL-P) had a lower particle number and protein content than the controls. The LDL-P was more resistant to cupric ion-mediated oxidation. HDL 2 from the patient (HDL 2 -P) had highly enhanced paraoxonase activity and antioxidant ability. The patient had a 1.5-fold higher level of apolipoprotein (apo) A-I expression in HDL 2 . ApoA-I in HDL 2 and HDL 3 from the patient showed no fragmentation, while the control had fragmented bands (17 and 21 kDa) in the HDL. The HDL 2 -P also had a larger particle size and greater protein content with less lipid content. HDL 3 -associated cholesteryl ester transfer protein was reduced in the patient, although the particle size was similar to the controls. In conclusion, a patient who had a markedly lower LDL-C/TC ratio despite hyperlipidemia associated with higher paraoxonase activity, higher apoA-I level and lower CETP activity without fragmentation of apoA-I in the HDL fraction is presented. The enhanced antioxidant and anti-inflammatory activity of HDL might contribute to the low LDL-C/TC ratio in this patient.
IntroductionDyslipidemia is an important risk factor for coronary heart disease (CHD), and low-density lipoprotein-cholesterol (LDL-C) is a strong biomarker to predict the risk of CHD (1). Patients with diabetes and metabolic syndrome have a strong association with atherogenic dyslipidemia, which includes high levels of triacylglycerides (TG) and elevated levels of small dense LDL (2). The most widely used method to calculate LDL-C is the Friedewald equation (3), although several methods of direct measurement are currently used. However, the estimated LDL-C using the Friedewald equation does not produce an accurate number when the plasma TG is >400 mg/dl or when plasma is not collected in the fasting state (4). Otherwise, a discrepancy in the number of measured LDL-C and the Friedewald LDL-C might indicate a modified lipoprotein metabolism. The National Cholesterol Education Program (NCEP) guidelines recommend development of direct assays to measure LDL-C (5) since LDL-C can be influenced by the dynamic interaction of apolipoprotein and several lipoprotein-associat...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.